2023-504509-36-00CompletedPhase 1
Bioequivalence study of a proposed biosimilar insulin glargine U300 with Toujeo®
Source: EU CTIS (euclinicaltrials.eu) · Last updated 20 Jun 2023
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 68 (actual)
- First submitted
- 30 Mar 2023
- Start date
- 19 Jul 2023
- Lead sponsor
- Biocon Sdn. Bhd.
- Diseases
- Type 1 diabetes
- EU CT number
- 2023-504509-36-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 68
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| PROFIL Institut fuer Stoffwechselforschung GmbH | Neuss | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.